Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
mi
from
Spartanburg, SC
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
Rapid City Regional Hospital
mi
from
Rapid City, SD
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
Rapid City Regional Hospital
mi
from
Rapid City, SD
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
Avera Cancer Institute
mi
from
Sioux Falls, SD
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
Avera Cancer Institute
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
Medical X-Ray Center, PC
mi
from
Sioux Falls, SD
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
Medical X-Ray Center, PC
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
Sanford Cancer Center at Sanford USD Medical Center
mi
from
Sioux Falls, SD
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
Sanford Cancer Center at Sanford USD Medical Center
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
Fredericksburg Oncology, Incorporated
mi
from
Fredericksburg, VA
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
Fredericksburg Oncology, Incorporated
mi
from
Fredericksburg, VA
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
Cascade Cancer Center at Evergreen Hospital Medical Center
mi
from
Kirkland, WA
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
Cascade Cancer Center at Evergreen Hospital Medical Center
mi
from
Kirkland, WA
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
Olympic Medical Center
mi
from
Port Angeles, WA
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
Olympic Medical Center
mi
from
Port Angeles, WA
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
Southlake Clinic
mi
from
Renton, WA
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
Southlake Clinic
mi
from
Renton, WA
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
CCOP - Virginia Mason Research Center
mi
from
Seattle, WA
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
CCOP - Virginia Mason Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
Southwest Washington Medical Center Cancer Center
mi
from
Vancouver, WA
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
Southwest Washington Medical Center Cancer Center
mi
from
Vancouver, WA
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
Central Wisconsin Cancer Program at Agnesian HealthCare
mi
from
Fond du Lac, WI
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
Central Wisconsin Cancer Program at Agnesian HealthCare
mi
from
Fond du Lac, WI
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
Green Bay Oncology, Limited at St. Mary's Hospital
mi
from
Green Bay, WI
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
Green Bay Oncology, Limited at St. Mary's Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
St. Mary's Hospital Medical Center - Green Bay
mi
from
Green Bay, WI
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
St. Mary's Hospital Medical Center - Green Bay
mi
from
Green Bay, WI
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
Franciscan Skemp Healthcare - La Crosse Campus
mi
from
La Crosse, WI
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
Franciscan Skemp Healthcare - La Crosse Campus
mi
from
La Crosse, WI
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
Bay Area Cancer Care Center at Bay Area Medical Center
mi
from
Marinette, WI
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
Bay Area Cancer Care Center at Bay Area Medical Center
mi
from
Marinette, WI
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
Green Bay Oncology, Limited - Oconto Falls
mi
from
Oconto Falls, WI
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
Green Bay Oncology, Limited - Oconto Falls
mi
from
Oconto Falls, WI
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
Green Bay Oncology, Limited - Sturgeon Bay
mi
from
Sturgeon Bay, WI
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
Green Bay Oncology, Limited - Sturgeon Bay
mi
from
Sturgeon Bay, WI
Click here to add this to my saved trials
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  9/14/2015
Welch Cancer Center at Sheridan Memorial Hospital
mi
from
Sheridan, WY
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 9/14/2015
Welch Cancer Center at Sheridan Memorial Hospital
mi
from
Sheridan, WY
Click here to add this to my saved trials
Capecitabine, Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer
A Dose Escalating (Phase I) Study Looking at the Biomodulation of Capecitabine by Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated:  9/15/2015
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Capecitabine, Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer
A Dose Escalating (Phase I) Study Looking at the Biomodulation of Capecitabine by Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated: 9/15/2015
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Capecitabine, Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer
A Dose Escalating (Phase I) Study Looking at the Biomodulation of Capecitabine by Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated:  9/15/2015
Ohio State University
mi
from
Columbus, OH
Capecitabine, Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer
A Dose Escalating (Phase I) Study Looking at the Biomodulation of Capecitabine by Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated: 9/15/2015
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Gemcitabine, Infusional 5 Fluorouracil and Bevacizumab in Patients With Advanced Pancreas Cancer
A Phase II Study of the Combination of Fixed Dose Rate Gemcitabine, Infusional 5 Fluorouracil and Bevacizumab in Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated:  9/15/2015
University of Michigan
mi
from
Ann Arbor, MI
Gemcitabine, Infusional 5 Fluorouracil and Bevacizumab in Patients With Advanced Pancreas Cancer
A Phase II Study of the Combination of Fixed Dose Rate Gemcitabine, Infusional 5 Fluorouracil and Bevacizumab in Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated: 9/15/2015
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Gemcitabine, Infusional 5 Fluorouracil and Bevacizumab in Patients With Advanced Pancreas Cancer
A Phase II Study of the Combination of Fixed Dose Rate Gemcitabine, Infusional 5 Fluorouracil and Bevacizumab in Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated:  9/15/2015
The Ohio State University James Cancer Hospital
mi
from
Columbus, OH
Gemcitabine, Infusional 5 Fluorouracil and Bevacizumab in Patients With Advanced Pancreas Cancer
A Phase II Study of the Combination of Fixed Dose Rate Gemcitabine, Infusional 5 Fluorouracil and Bevacizumab in Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated: 9/15/2015
The Ohio State University James Cancer Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Engaging Diverse Underserved Communities to Bridge the Mammography Divide
Engaging Diverse Underserved Communities to Bridge the Mammography Divide
Status: Enrolling
Updated:  9/15/2015
University of Kansas Medical Center
mi
from
Kansas City, KA
Engaging Diverse Underserved Communities to Bridge the Mammography Divide
Engaging Diverse Underserved Communities to Bridge the Mammography Divide
Status: Enrolling
Updated: 9/15/2015
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy
Phase II Study of Pralatrexate and Docetaxel in Patients With Advanced Esophageal and Gastroesophageal Carcinoma Who Have Failed Prior Platinum-based Therapy.
Status: Enrolling
Updated:  9/15/2015
Ohio State University
mi
from
Columbus, OH
Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy
Phase II Study of Pralatrexate and Docetaxel in Patients With Advanced Esophageal and Gastroesophageal Carcinoma Who Have Failed Prior Platinum-based Therapy.
Status: Enrolling
Updated: 9/15/2015
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Prone Patient Positioning in Reducing Tumor Motion and Improving Breathing Reproduction in Patients With Lung Cancer Undergoing Radiation Therapy
Pulmonary Tumor Motion Reduction and Improved Breathing Reproducibility by Prone Patient Positioning in Radiation Therapy
Status: Enrolling
Updated:  9/16/2015
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Prone Patient Positioning in Reducing Tumor Motion and Improving Breathing Reproduction in Patients With Lung Cancer Undergoing Radiation Therapy
Pulmonary Tumor Motion Reduction and Improved Breathing Reproducibility by Prone Patient Positioning in Radiation Therapy
Status: Enrolling
Updated: 9/16/2015
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Providence Health System - Southern California d/b/a Roy and Patricia Disney Family Cancer Center
mi
from
Burbank, CA
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Providence Health System - Southern California d/b/a Roy and Patricia Disney Family Cancer Center
mi
from
Burbank, CA
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
University of Southern California
mi
from
Los Angeles, CA
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
University of Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
PMK Medical Group, Inc., dba Ventura County Hematology Oncology Specialists
mi
from
Oxnard, CA
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
PMK Medical Group, Inc., dba Ventura County Hematology Oncology Specialists
mi
from
Oxnard, CA
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Stanford University School of Medicine
mi
from
Stanford, CA
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Kaiser Permanente
mi
from
Vallejo, CA
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Kaiser Permanente
mi
from
Vallejo, CA
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Rocky Mountain Cancer Centers
mi
from
Denver, CO
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Rocky Mountain Cancer Centers
mi
from
Denver, CO
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Pre clinical Science Bldg LR3
mi
from
Washington,
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Pre clinical Science Bldg LR3
mi
from
Washington,
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Medstar
mi
from
Washington DC,
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Medstar
mi
from
Washington DC,
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Mayo Clinic Florida
mi
from
Jacksonville, FL
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Mayo Clinic Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Advanced Medical Specialties
mi
from
Miami, FL
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Advanced Medical Specialties
mi
from
Miami, FL
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Florida Cancer Research Institute
mi
from
Plantation, FL
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Florida Cancer Research Institute
mi
from
Plantation, FL
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Hematology Oncology Associates Of The Treasure Coast
mi
from
Port St. Lucie, FL
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Hematology Oncology Associates Of The Treasure Coast
mi
from
Port St. Lucie, FL
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Northeast Georgia Cancer Care
mi
from
Athens, GA
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Northeast Georgia Cancer Care
mi
from
Athens, GA
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Peachtree Hematology-Oncology Consultants
mi
from
Atlanta, GA
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Peachtree Hematology-Oncology Consultants
mi
from
Atlanta, GA
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Emory University
mi
from
Atlanta, GA
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Central Georgia Cancer Care
mi
from
Macon, GA
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Central Georgia Cancer Care
mi
from
Macon, GA
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Summit Cancer Care
mi
from
Savannah, GA
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Summit Cancer Care
mi
from
Savannah, GA
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
University of Chicago Medicine
mi
from
Chicago, IL
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
University of Chicago Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
IU Health Simon Cancer Center
mi
from
Indianapolis, IN
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
IU Health Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Hall-Perrine Cancer Center, 3rd Floor
mi
from
Cedar Rapids, IA
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Hall-Perrine Cancer Center, 3rd Floor
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Kansas City Cancer Center, LLC
mi
from
Overland Park, KA
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Kansas City Cancer Center, LLC
mi
from
Overland Park, KA
Click here to add this to my saved trials
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated:  9/17/2015
Louisville Oncology Clinical Research Program
mi
from
Louisville, KY
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine
Status: Enrolling
Updated: 9/17/2015
Louisville Oncology Clinical Research Program
mi
from
Louisville, KY
Click here to add this to my saved trials